Muscle quantitative MRI as a novel biomarker in hereditary transthyretin amyloidosis with polyneuropathy: a cross-sectional study
暂无分享,去创建一个
N. Bergsland | E. Marchioni | A. Pichiecchio | X. Deligianni | M. Paoletti | G. Cosentino | C. Tassorelli | G. Merlini | F. Santini | E. Alfonsi | R. Mussinelli | S. Bastianello | L. Obici | G. Palladini | A. Cortese | A. Lozza | Elisa Vegezzi | Francesca Solazzo | R. Currò | I. Callegari | R. Curró | Ilaria Quartesan | Lucia Ascagni | E. Vegezzi
[1] N. Bergsland,et al. Deep learning for automatic segmentation of thigh and leg muscles , 2021, Magnetic Resonance Materials in Physics, Biology and Medicine.
[2] M. Froeling,et al. 3D Automated Segmentation of Lower Leg Muscles Using Machine Learning on a Heterogeneous Dataset , 2021, Diagnostics.
[3] N. Bergsland,et al. Reproducibility of manual segmentation in muscle imaging , 2021, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.
[4] M. Maitland,et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. , 2021, The New England journal of medicine.
[5] Oliver Bieri,et al. Fast Open-Source Toolkit for Water T2 Mapping in the Presence of Fat From Multi-Echo Spin-Echo Acquisitions for Muscle MRI , 2021, Frontiers in Neurology.
[6] S. Heiland,et al. Magnetization transfer ratio quantifies polyneuropathy in hereditary transthyretin amyloidosis , 2020, Annals of clinical and translational neurology.
[7] R. Finkel,et al. Modeling disease trajectory in Duchenne muscular dystrophy , 2020, Neurology.
[8] Augustin C. Ogier,et al. Fat fraction distribution in lower limb muscles of patients with CMT1A , 2020, Neurology.
[9] P. Dyck,et al. Transthyretin amyloidosis: Putting myopathy on the map , 2020, Muscle & nerve.
[10] Hakmook Kang,et al. Length‐dependent MRI of hereditary neuropathy with liability to pressure palsies , 2019, Annals of clinical and translational neurology.
[11] I. Wilkinson,et al. Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease , 2019, Journal of Neurology.
[12] W. Litchy,et al. Development of measures of polyneuropathy impairment in hATTR amyloidosis: From NIS to mNIS + 7 , 2019, Journal of the Neurological Sciences.
[13] T. Hornemann,et al. Development of MRC Centre MRI calf muscle fat fraction protocol as a sensitive outcome measure in Hereditary Sensory Neuropathy Type 1 , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.
[14] A. Pichiecchio,et al. Advances in Quantitative Imaging of Genetic and Acquired Myopathies: Clinical Applications and Perspectives , 2019, Front. Neurol..
[15] L. Greensmith,et al. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity , 2018, Neurology.
[16] M. de Carvalho,et al. Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy , 2018, Neurology.
[17] S. Solomon,et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[18] S. Solomon,et al. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.
[19] G. Fink,et al. MRI biomarkers of proximal nerve injury in CIDP , 2017, Annals of clinical and translational neurology.
[20] S. Ayache,et al. Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial , 2017, Muscle & nerve.
[21] W. Litchy,et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy , 2017, BMC Neurology.
[22] S. Heiland,et al. Sural nerve injury in familial amyloid polyneuropathy , 2017, Neurology.
[23] S. Friedman,et al. Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients , 2016, Neurology.
[24] H. Reyngoudt,et al. Simultaneous muscle water T2 and fat fraction mapping using transverse relaxometry with stimulated echo compensation , 2016, NMR in biomedicine.
[25] M. Russo,et al. Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area , 2016, Journal of Neurology.
[26] T. Yousry,et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study , 2016, The Lancet Neurology.
[27] B. Bettencourt,et al. Rapid progression of familial amyloidotic polyneuropathy , 2015, Neurology.
[28] Matthias Weigel,et al. Extended phase graphs: Dephasing, RF pulses, and echoes ‐ pure and simple , 2015, Journal of magnetic resonance imaging : JMRI.
[29] S. Heiland,et al. In vivo detection of nerve injury in familial amyloid polyneuropathy by magnetic resonance neurography , 2014, Brain : a journal of neurology.
[30] B. Bettencourt,et al. Retrospective study of a TTR FAP cohort to modify NIS+7 for therapeutic trials , 2014, Journal of the Neurological Sciences.
[31] E. Nordh,et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.
[32] I. Merkies. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial , 2013, Neurology.
[33] J. Albers,et al. "Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial. , 2012, Archives of neurology.
[34] Joel Kullberg,et al. Three‐dimensional water/fat separation and T 2* estimation based on whole‐image optimization—Application in breathhold liver imaging at 1.5 T , 2012, Magnetic resonance in medicine.
[35] O. Bieri,et al. Quantitative MRI can detect subclinical disease progression in muscular dystrophy , 2012, Journal of Neurology.
[36] G. Sobue,et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[37] W. Litchy,et al. Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial , 2010, Muscle & nerve.
[38] Y. Ando,et al. Liver Transplantation for Familial Amyloidotic Polyneuropathy (FAP): A Single‐Center Experience Over 16 Years , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] G. Sobue,et al. Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy , 2004, Neurology.
[40] C. Lacroix,et al. Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy , 1998, Neurology.
[41] W. Litchy,et al. Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort , 1997, Neurology.
[42] P. Dyck,et al. The natural history of peripheral neuropathy in primary systemic amyloidosis , 1979, Annals of neurology.
[43] X. Deligianni,et al. Intra-rater and Inter-rater Reliability of Quantitative Thigh Muscle Magnetic Resonance Imaging , 2019 .